Preclinical work in syngeneic mice and rats inoculated with BC cell lines and treated with anti-PD-L1 ICI in conjunction with BCG led to a tumor weight reduction and increased cytotoxic T cell immune responses as compared to BCG alone [28, 29]. The gene discussed is CD274; the disease is neoplasm.